Relationship of nonalcoholic hepatic steatosis to overnight low‐dose dexamethasone suppression test in obese individuals
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Summary: objectives To examine the association between nonalcoholic hepatic steatosis (HS) and the activity of the hypothalamo–pituitary–adrenal (HPA) axis, as evaluated by a low‐dose dexamethasone suppression test, in obese subjects. design and patients In a cross‐sectional study, we examined 54 obese, otherwise healthy, individuals with a negligible or zero daily alcohol consumption. measurements HS (by ultrasonography), glucose tolerance status (by oral glucose load), insulin resistance [by homeostasis model assessment (HOMA)] and 1·0 mg postdexamethasone (postdex) suppression cortisol levels were measured. results Subjects with nonalcoholic HS (n = 39) had markedly less suppressed circulating cortisol levels than those without HS (n = 15) (21·9 ± 2·6 vs. 11·0 ± 1·4 nmol/l, P < 0·001). In addition, subjects with nonalcoholic HS had significantly higher values of HOMA‐insulin resistance score and circulating liver enzymes than their counterparts without HS. Age, body mass index (BMI), waist/hip ratio, plasma glucose concentration (both at fasting and after glucose load), lipids and blood pressure values did not differ significantly between the groups. Females were more represented among those without HS. The marked differences in postdex suppression cortisol levels that were observed between the groups were little affected by adjustment for sex, age, BMI, waist/hip ratio, HOMA‐insulin resistance score, plasma lipids and liver enzyme levels. Similarly, in a logistic regression analysis, cortisol levels significantly predicted the presence of nonalcoholic HS (P = 0·032), independently of potential confounders. conclusions These results suggest that nonalcoholic hepatic steatosis is closely correlated with a subtle, chronic activation of the HPA axis in obese, otherwise healthy, individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766
Diagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362
Does central obesity reflect “Cushing's disease of the omentum”?
Bujalska, I. J., Kumar, S., & Stewart, P. M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11222-8 · Cited by 753 · cited 2×
“…from its inactive 11- keto metabolite cortisone within adipose tissue by 11beta HSD1 has been proposed to cause visceral fat accumulation and type 2 diabetes, whereas decreased hepatic 11beta HSD-1 may protect the liver from glucocorticoid excess (Bujalska et al ., 1997; Stulnig & Waldhausl, 2004).”
BackgroundGlucocorticoids and insulin resistance: old hormones, new targets
ANDREWS, R. C., & WALKER, B. R. (1999) · Clinical Science · doi:10.1042/cs0960513 · Cited by 731 · cited 3×
“…abnormal regulation of glucocorticoid metabolism, highlighted by the clinical similarities between the sequelae of insulin resistance and Cushing’s syndrome, as well as the functional antagonism of glucocorticoids to insulin (Andrew et al ., 1998; Andrews & Walker, 1999; Bjorntorp & Rosmond, 1999).”
Background
Cited by
Mechanisms of Glucocorticoid-Induced Insulin Resistance
Geer, E. B., Islam, J., & Buettner, C. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.10.005 · Cited by 392
11β-hydroxysteroid dehydrogenase 1: translational and therapeutic aspects
Gathercole, L. L., Lavery, G. G., Morgan, S. A., Cooper, M. S., Sinclair, A. J., Tomlinson, J. W., & Stewart, P. M. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1050 · Cited by 196
Cushing’s syndrome in a clinic population with diabetes
Newsome, S., Chen, K., Hoang, J., Wilson, J. D., Potter, J. M., & Hickman, P. E. (2008) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2007.01434.x · Cited by 48
The pituitary–adrenal axis and body composition
Fernandez-Rodriguez, E., Stewart, P. M., & Cooper, M. S. (2009) · Pituitary · doi:10.1007/s11102-008-0098-2 · Cited by 49
Holt, H. B., Wild, S. H., Postle, A. D., Zhang, J., Koster, G., Umpleby, M., Shojaee-Moradie, F., Dewbury, K., Wood, P. J., Phillips, D. I., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0629-9 · Cited by 48
“Previously it has been shown that obese individuals [12] and overweight people with type 2 diabetes [31] with fatty liver have higher 24-h urinary free cortisol excretion with impaired dexamethasone suppression of cortisol compared with control subjects.”
Metadata
- Authors
- Zoppini, G., Targher, G., Venturi, C., Zamboni, C., & Muggeo, M.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2004-10-29
- Volume
- 61
- Issue
- 6
- Pages
- 711-715
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W1996004606
- Cited by
- 30
- References
- 4
- FWCI
- 1.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Relationship of nonalcoholic hepatic steatosis to overnight low‐dose dexamethasone suppression test in obese individuals. https://app.cochat.ai/papers/10.1111/j.1365-2265.2004.02154.x
- The paper
- Zoppini, G., Targher, G., Venturi, C., Zamboni, C., & Muggeo, M. (2004). Relationship of nonalcoholic hepatic steatosis to overnight low‐dose dexamethasone suppression test in obese individuals. Clinical Endocrinology. https://doi.org/10.1111/j.1365-2265.2004.02154.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.